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Background and objectives: The number of patients treated with oral anticoagulation (OAC) is increasing and
these patients are monitored by International Normalized Ratio (INR). Bleeding complications are common and we
speculate if this is related to the limitation of INR only reflecting the initiation steps of the haemostatic process. The
objective of the present review was to reassess the evidence for using INR as a tool to guide administration of
prothrombin complex concentrates (PCC) to OAC patients. A Medline and Cochrane database search was
conducted using the following keywords: prothrombin complex concentrate, reversal of oral anticoagulation and
international normalized ratio (INR). Thirty-three articles were contracted and a total of ten studies were eligible after
applying inclusion and exclusion criteria encompassing only 339 patients. No consensus regarding optimal target
INR value to aim for when reversing OAC was found. In three of the studies it was reported that patients reaching
their target INR continued to bleed, whereas three studies reviewed reported good haemostatic response also in
patients that did not reach their target INR. The present review found limited evidence for the usefulness of INR as
a tool to monitor and guide reversal of OAC induced coagulopathy in patients with PCC, which is expected given
that it is a plasma-based assay only reflecting a limited part of the haemostatic process.
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More and more people in the economically developed
world are treated with oral anticoagulants due to the
increasing proportion of elderly and the well documen-
ted effectiveness of anticoagulants to prevent primary
and secondary thromboembolic events [1,2]. The most
commonly used oral anticoagulants (OAC) are the
synthetic coumarin derivatives warfarin, acenocoumarol
and phenprocoumon, which are indicated in patients
with atrial fibrillation and prosthetic cardiac valves [2].
Even though new oral anticoagulants have recently been
introduced such as Dabigatran (FIIa inhibitor), and
Apixaban (FXa inhibitor) which are being implemented as
preventive drugs after knee and hip replacement surgery
to avoid post operative complications [3], coumarin is still* Correspondence: sacha@solbeck.dk
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reproduction in any medium, provided the orthe drug must often chosen because it is cheap and well-
documented. Synthetic coumarin derivates act by inhibit-
ing synthesis of K-vitamin dependent coagulation factors
II, VII, IX and X thereby inhibiting/reducing thrombin
generation [4]. Treatment with coumarin derivates is
associated with an increased incidence of bleeding, which
is found to be a recognized complication affecting approxi-
mately 1% of the patients treated with OAC and about half
of these patients die from bleeding complications annually
[5]. Current treatment of choice for rapid reversal of
patients on OAC in case of bleeding or need for acute
surgery is prothrombin complex concentrate (PCC)
encompassing coagulation factor II, VII, IX, X as well as
Protein C and S [1]
Patients treated with OAC are routinely monitored by
a coagulation analysis based on the prothrombin time
(PT) that was introduced more than 50 years ago, whenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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only in the plasma [6].
With the introduction of the cell-based model of
haemostasis it became apparent that these assays only
reflect the initiation step of the haemostatic process [7].
Therefore, whole blood viscoelastical assays (VHA), such
as thrombelastography (TEG) or rotational thrombelasto-
metry (ROTEM), that analyze the viscoelastic properties
of clot formation in whole blood, including the patient’s
ability to generate the thrombin, thereby reflecting the
entire haemostatic process, these may be valuable in
addition to plasma-based coagulation assays in OAC
patients [8]. VHA has been reported to better predict
transfusion requirements than PT and INR and are recom-
mended by recent international guidelines for massively
bleeding patients [9]. It should be noted, however, that no
randomized clinical trial has been performed comparing
the value of VHA vs. INR in predicting bleeding in OAC
patients and consequently the value of VHA in this setting
remains elusive.
The appropriateness of INR as a tool to monitor and
guide OAC may be questioned by reviewing the litera-
ture concerning administration of PCC to reverse OAC
treatment rapidly since coagulation factors II, VII, IX
and X hereby is administered specifically and these are
supposed to be reflected by this assay. The aim of the
present review was, therefore, to provide an overview of
the current literature reporting on the effect of adminis-
tration of PCC to OAC patients prior to surgical inter-
vention or in the event of bleeding and more specifically
to review its effect on correction of INR as well as the
association with achievement of haemostasis.
Method
A literature search was conducted from PubMed and
Cochrane Library with the aim of contracting articles
reporting the use of PCC for reversal of OAC patients
prior to surgical interventions or in the event of active
bleeding, who were reporting the effect of the interven-
tion on both INR and on clinical efficacy.
The search was conducted using the following key words:
Prothrombin complex concentrate, reversal of oral anticoa-
gulation, international normalized ratio. ("prothrombin
"[MeSH Terms] OR "prothrombin"[All Fields]) AND com-
plex[All Fields] AND concentrate[All Fields] AND Reversal
[All Fields] AND ("mouth"[MeSH Terms] OR "mouth"[All
Fields] OR "oral"[All Fields]) AND anticoagulation[All
Fields] AND ("international normalised ratio"[All Fields]
OR "international normalized ratio"[MeSH Terms] OR
("international"[All Fields] AND "normalized"[All Fields]
AND "ratio"[All Fields]) OR "international normalized
ratio"[All Fields]).
The following inclusion criteria were applied: 1.
English language, 2. Human study, 3. Administration ofPCC to reverse anticoagulation in bleeding patients or
patients undergoing surgery, 4. Reporting end points
including both effect on INR and clinical efficacy.
Exclusion criteria applied were: 1. In vitro studies and
2. Dental procedures.
Results
Thirty-three articles were identified in the Medline
search, whereas no articles were found in the Cochrane
Database. After applying inclusion and exclusion criteria
seven articles remained and another three studies were
identified through the references of the identified reports
totalling ten eligible studies (Table 1.)
Randomised controlled studies (RCT)
Two RCT were identified. Demeyere et al. [10] compared
the efficacy of intraoperative administration of PCC or
FFP in 40 OAC patients undergoing heart surgery of
whom 20 patients received PCC based on weight, initial
and target INR (<1.5 or 1.5). None of the patients
suffered from abnormal bleeding post-CPB surgery
though only 6 had reached target INR after 60 minutes.
A total of 33 RBC units were transfused to the PCC
group. No thromboembolic events were reported.
Van Aart et al. [11] investigated in 93 OAC patients
the efficacy of a standard dosage of PCC (Group A) as
compared to an individualized dosage (Group B) on
reaching target INR (minor bleeding or intervention:
<2.1 or 2.1, major bleeding: <1.5 or 1.5) and bleeding.
Group A received a single PCC dose (7IU/kg) and 43%
reached target INR after 15 minutes whereas 89%
reached their target INR in group B. Four patients (3 in
Group A and 1 in Group B) continued to bleed even
though they had reached target INR. No FFP or platelet
concentrates were administered, no information on
transfusion of packed red blood cells. Two cerebral
thrombotic events occurred, one in each group.
Prospective observational studies
Pabinger et al. [12] evaluated the efficacy and safety of
PCC (Beriplex P/N) in 43 patients who either were in
need of intervention (N= 26) or demonstrated active
bleeding (N= 17) at a dose of 25-35-50IU/kg depending
on initial INR. In 93% of the patients INR was reduced
to below the target INR of 1.3 and in 98% of the patients
the clinical efficacy was rated ’very good’ or ’satisfactory’.
One patient was judged ‘questionable’ because of persist-
ent bladder bleeding. No information on transfusions
reported. One fatal pulmonary embolism was reported
which was judged to be possibly treatment related.
Lorenz et al. [13] evaluated the effectiveness and safety
of PCC for emergency reversal of OAC in 8 patients
undergoing invasive procedures or demonstrating active
bleeding. Median Beriplex P/N dose was 57IU/kg and
Table 1 Description of the type of studies, number of patients included and patient group, dose of PCC, target INR, outcome 1 and 2, transfusions and
thromboembolic events
Author Study No. Area Interventiondose
PCC/kg
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Table 1 Description of the type of studies, number of patients included and patient group, dose of PCC, target INR, ou come 1 and 2, transfusions and
thromboembolic events (Continued)






























































































Sølbeck et al. Thrombosis Journal 2012, 10:5 Page 6 of 8
http://www.thrombosisjournal.com/content/10/1/5two patients needed a second dose of 1500IU and
3500IU, respectively, to reach target INR (no target value
listed). Clinical effectiveness was rated by cessation of
bleeding and 7/8 was rated ’very good’ and 1/8 as ’satis-
factory’. No transfusions were administered and no
thrombembolic events were reported.
Riess et al. [14] investigated 60 patients in need of
reversal of OAC treatment before surgery. Octaplex was
administered at a mean dose of 41IU/kg and 90% reached
target INR being 1.1-1.3 for major surgery or invasive
procedures and 1.5-2.1 for minor surgery or other invasive
procedures. Clinical efficacy was rated ’excellent’ in all
patients by the surgeon. No transfusions or thrombo-
embolic events were reported.
Yasaka et al. [15] investigated the optimal PCC dose
for acute OAC reversal in 27 patients with cerebral
haemorrhage and in 15 patients with major haemorrhagic
complications or patients who were to undergo invasive
procedures without defining a target INR value. Thirty
patients received 9IU/kg decreasing INR from 2.5 to 1.2.
Another group of patients received 18IU- 26IU/kg and
INR decreased from 2.3 to 1.0. In the patients who had
cerebral haemorrhages the haematomas enlarged in two
cases despite normalization of INR. Bleeding ceased in the
non-neurological haemorrhage group after administration
of PCC.
Lavenne-Pardonge et al. [16] investigated the use of
PPSB-SD for reversal of OAC within 15 minutes in 14
patients, aiming for a target INR of <2.0 for moderate
haemorrhage and abdominal surgery and <1.5 for severe
haemorrhage and cardiovascular interventions. Data
were missing on two patients and 11/12 of the remaining
patients reached target INR and bleeding arrested in the
6 patients treated for ongoing bleeding. No transfusions
or thromboembolic events were reported.
Lubetsky et al. [17] reported an open-labelled phase II-
study were efficacy and safety of Octaplex for rapid
reversal of OAC was evaluated without defining a target
INR value for the intervention.
Twenty patients were enrolled (10 in a active bleeding
group and 10 in a surgery group). Mean INR declined
from 6.1 ± 2.8 to 1.5 ± 0.3.A three-point scale was used
for evaluation of clinical efficacy and in the bleeding group
9/10 was rated ’good’ and 1/10 was rated ’moderate’. In the
surgery group 8/10 was rated ’good’ and 2/10 ’moderate’. It
was not specified which patients had normalized their
INR. The three patients who were rated ’moderate’ were
transfused with 2-7 units of packed cells. No thrombo-
embolic events were reported.
Retrospective studies
Schick et al. [18] reviewed 50 patients of whom 12 were
OAC patients receiving Beriplex P/N. The median dose
administered was 1500IU or 22IU/kg and target INR wasless than 1.7. Mean INR decreased significantly from
baseline INR 2.8 ± 0.2 to 1.5 ± 0.1.
Interestingly no major per operative bleeding was
reported despite that one patient received RBC, FFP and
platelet concentrate after PCC administration. No
thromboembolic events were seen.
Chong et al. [19] investigated 7 neurological OAC
patients with intracranial haemorrhage and receiving 3-
factor PCC (Profilnine SD). Median dose of PCC was
28IU/kg and median time to normalization of INR
(defined as INR less than 1.5) was 420 minutes. Three
patients died, two because of haematoma growth despite
PCC administration. One patient experienced a pulmonary
embolism.
Discussion
Double-blind randomized clinical trials evaluating the
suitability of INR to guide PCC reversal in OAC treated
patients are lacking and the result of the present review
do not allow for any such conclusion either.
Unfortunately the search only identified 10 studies
involving merely 339 patients where the effect of PCC
on INR and haemostasis was investigated and half of the
studies involved less than 30 patients each. The low
number of patients investigated is somewhat surprising
considering that in UK alone more than 1 million
patients are on OAC [20] and that the number of OAC
patients is steadily increasing [21].
Apart from the low number of patients investigated, it
was difficult to assess the clinical utility of INR as a tool to
monitor OAC patients due to considerable heterogeneity
in the studies evaluated. Firstly, no consensus appeared to
exist regarding what target INR value that is appropriate
to aim for when reversing of OAC is considered since this
varied from 1.1 to 2.1. Furthermore, considerable differ-
ences in PCC doses were used in the studies investigated
and also different PCC products containing different levels
of vitamin K dependent coagulation factors were adminis-
tered making it impossible to delineate a possible relation
between the units of coagulation factor activity adminis-
tered and its effect on the INR. This is further corrobo-
rated by a recent American College of Chest Physicians
Evidenced-based Clinical Guidelines not providing any
guidance on optimal target INR or optimal dosage regard-
ing reversal with PCC [22].
In regard to the association between INR and haemosta-
sis this is obviously challenging given the methodological
problem presented above and furthermore the evaluation
of the haemostatic response to PCC resulting in a lowered
INR was not standardized with some studies using transfu-
sions and clinical judgement [10,18] as endpoints and
others using only clinical judgement [11-17,19]. Despite
this, however, we found that at least 10/339 (3%) patients
continued to bleed despite reaching their target INR.
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the most common cause of medical emergency depart-
ment visits in the US accounting for more than 15% of the
170.000 estimated visits each year [23]. Furthermore,
Demeyere et al. [10] reported no abnormal bleeding in the
9 out of 16 patient’s not reaching target INR and undergo-
ing cardiac surgery and Riess et al. [14] also found a good
clinical response in 5 patients not reaching target INR and
collectively they report that in the 22% of the patients not
reaching target INR normal haemostasis was observed fur-
ther indicating that this analytical method is associated
with significant clinical limitations. This is in alignment
with Segal et al. [24] who in a review reported that abnor-
mal coagulation tests such as INR did not predict bleeding
in patients undergoing invasive procedures. Hence, we do
not infer that a cohort of OAC patients with a prolonged
INR has increased bleeding risk as compared to OAC
patients with a normal INR but instead point towards the
ability of INR to predict bleeding risk for the individual
OAC patient.
It is well established that conventional coagulation
assays do not identify hypercoagulability [25] i.e. increased
thrombotic risk and this is corroborated in the present re-
view by the finding that four (1.8%) patients with a normal
INR value developed thrombembolic events.
In recent years systematic use of whole blood visco-
elastic assays such as TEG and ROTEM has improved
transfusion therapy and outcome in surgical patients in-
cluding trauma [25]. More than 25 studies including
three randomized controlled studies all report that TEG/
ROTEM better predict bleeding and need for transfusion
than routine coagulation analysis and also that transfu-
sion requirements and need for re-do surgery is lower in
patients treated based on TEG/ROTEM [26]. The scien-
tific rationale for this difference is that TEG/ROTEM as-
sess haemostasis in whole blood including the platelets
and thereby enable evaluation of all three phases of clot
generation (initiation, amplification, propagation) as well
as the physical characteristics of the formed clot [26] and
we speculate whether monitoring OAC patients with
these assays might be beneficial.
The present review has limitations such as only includ-
ing studies where PCC was evaluated and where INR
was used to monitor the degree of anticoagulation. Fur-
thermore, restricting our search to English language
reports may also have omitted relevant studies.
In conclusion the present review found limited evidence
for the usefulness of INR alone as a tool to monitor and
guide reversal of OAC patients with PCC, which is
expected given that it is a plasma-based assay. We suggest
INR being used in conjunction with whole blood visco-
elastic assays and well-designed randomized controlled
trials evaluating these whole blood viscoelastic assays
compared to INR in this setting are warranted.Competing interests
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